Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-05-01 Epub Date: 2023-10-10 DOI:10.2217/fon-2023-0615

Charles Dharmani, Sudhir Unni, Ngan Pham, Nazneen Fatima Shaikh, Yan Xiong, Rohan Vashi, Oluwatosin Fofah, Alessandria Strubing, Maribel Salas, Nora Tu, Margaret Wooddell, Xiaoyu Zhou, Aimee Near

{"title":"Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.","authors":"Charles Dharmani, Sudhir Unni, Ngan Pham, Nazneen Fatima Shaikh, Yan Xiong, Rohan Vashi, Oluwatosin Fofah, Alessandria Strubing, Maribel Salas, Nora Tu, Margaret Wooddell, Xiaoyu Zhou, Aimee Near","doi":"10.2217/fon-2023-0615","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate treatment patterns, healthcare resource utilization (HRU) and costs among peripheral T-cell lymphoma (PTCL) patients in the USA. Methods: A retrospective cohort study, using the IQVIA PharMetrics® Plus claims database from 1 April 2011 to 30 November 2021, identified PTCL patients receiving systemic treatments. Three mutually exclusive subcohorts were created based on line of therapy (LOT): 1LOT, 2LOT and ≥3LOT. Common treatment regimens, median time on treatment, all-cause and PTCL-related HRU and costs were estimated. Results: Among 189 PTCL patients identified, 61.9% had 1LOT, 21.7% had 2LOT and 16.4% had ≥3LOT. The most common treatment regimens in the 1LOT were CHOP/CHOP-like, CHOEP/CHOEP-like and brentuximab vedotin; monotherapies were most common in the 2LOT and ≥3LOT. All-cause and PTCL-related hospitalizations and prescriptions PPPM increased with increasing LOT. Nearly 70% of total treatment costs were PTCL related. Conclusion: Higher utilization of combination therapies in the 1LOT and monotherapies in subsequent LOTs were observed, alongside high PTCL-related costs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1013-1030"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0615","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate treatment patterns, healthcare resource utilization (HRU) and costs among peripheral T-cell lymphoma (PTCL) patients in the USA. Methods: A retrospective cohort study, using the IQVIA PharMetrics^® Plus claims database from 1 April 2011 to 30 November 2021, identified PTCL patients receiving systemic treatments. Three mutually exclusive subcohorts were created based on line of therapy (LOT): 1LOT, 2LOT and ≥3LOT. Common treatment regimens, median time on treatment, all-cause and PTCL-related HRU and costs were estimated. Results: Among 189 PTCL patients identified, 61.9% had 1LOT, 21.7% had 2LOT and 16.4% had ≥3LOT. The most common treatment regimens in the 1LOT were CHOP/CHOP-like, CHOEP/CHOEP-like and brentuximab vedotin; monotherapies were most common in the 2LOT and ≥3LOT. All-cause and PTCL-related hospitalizations and prescriptions PPPM increased with increasing LOT. Nearly 70% of total treatment costs were PTCL related. Conclusion: Higher utilization of combination therapies in the 1LOT and monotherapies in subsequent LOTs were observed, alongside high PTCL-related costs.

查看原文本刊更多论文

外周T细胞淋巴瘤患者的真实世界治疗模式、医疗资源利用率和成本。

目的：评估美国外周T细胞淋巴瘤（PTCL）患者的治疗模式、医疗资源利用率（HRU）和成本。方法：2011年4月1日至2021年11月30日，使用IQVIA PharMetrics®Plus索赔数据库进行的一项回顾性队列研究，确定了接受全身治疗的PTCL患者。基于治疗线（LOT）创建了三个相互排斥的子项：1LOT、2LOT和≥3LOT。评估了常见的治疗方案、中位治疗时间、全因和PTCL相关的HRU和费用。结果：在189例PTCL患者中，61.9%的患者患有1LOT，21.7%的患者患有2LOT，16.4%的患者患有≥3LOT。1LOT中最常见的治疗方案是CHOP/CHOP样、CHOEP/CHOEP样和布伦妥昔单抗韦多汀；单一疗法在2LOT和≥3LOT中最为常见。所有原因和PTCL相关的住院和处方PPPM随着LOT的增加而增加。近70%的治疗费用与PTCL相关。结论：在1LOT中观察到联合治疗的利用率较高，在随后的LOT中观察到单一疗法的利用率也较高，同时PTCL相关费用也较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.